Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enzastaurin.

Shuo Ma1, Steven T Rosen

  • 1Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA.

Current Opinion in Oncology
|October 2, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiopaque microsphere-hydrogel composite for extended-release intratumoral immunotherapy in a large animal model.

Drug delivery and translational research·2026
Same author

Cellular senescence in musculoskeletal diseases: biological mechanisms and clinical implications.

Theranostics·2026
Same author

Relationship between cerebrospinal fluid neurobiomarkers and symptoms in older patients with cognitive impairment: an observational clinical study.

Scientific reports·2026
Same author

Inhibition of 5'-tiRNA<sup>Gly</sup> restores anti-PD-1 immunotherapy efficacy via DLST-mediated OGDHL succinylation in gastric cancer.

Journal of experimental & clinical cancer research : CR·2026
Same author

Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials.

The Lancet. Oncology·2026
Same author

Mechanisms influencing Chinese senior faculty's intention to engage in volunteer teaching and policy implications.

Frontiers in psychology·2026
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Enzastaurin, an oral antitumor drug, shows promise in treating advanced cancers by inhibiting protein kinase Cbeta and the AKT pathway. Clinical trials indicate it is well-tolerated and effective, particularly in diffuse large B-cell lymphoma.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Enzastaurin is a novel oral antitumor agent targeting protein kinase Cbeta.
  • It has shown potential in early-phase trials for various advanced cancers.

Purpose of the Study:

  • To review the mechanism of action, development, and clinical results of Enzastaurin.
  • To assess its efficacy and safety in hematologic malignancies and solid tumors.

Main Methods:

  • Preclinical studies evaluated antitumor effects on cancer cell lines and xenografts.
  • Phase I and II clinical trials assessed safety, dosage, and efficacy in cancer patients.

Main Results:

  • Enzastaurin inhibits protein kinase Cbeta and the phosphoinositide-3 kinase/AKT pathway.

Related Experiment Videos

  • The recommended oral dose is 525 mg/day, with good tolerability and no significant grade 3 or 4 toxicities.
  • Phase II studies in diffuse large B-cell lymphoma demonstrated prolonged freedom from progression.

    • Conclusions:

    • Enzastaurin is an emerging and promising antitumor treatment.
    • It can be safely used long-term in combination with chemotherapy for various advanced cancers.